I

t’s still early days for efforts to develop gene therapies against hemophilia, but a handful of patients treated with these one-time, potentially curative treatments have now been followed long enough to start measuring clinically relevant outcomes like reductions in bleeding episodes. That’s what matters most to hemophilia patients (and it’s what will form the basis of regulatory approvals), so it’s more significant than looking at surrogate markers of activity such as increases in the activity level of clotting factors.

On Tuesday, Biomarin announced plans to start a phase 3 study in the fourth quarter of its gene therapy BMN 270 for hemophilia A. The biotech company is moving forward with the high dose of BMN 270, which some will see as a controversial decision because Factor VIII activity levels exceeded normal limits in some patients treated in the phase 1-2 study.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy